4 research outputs found
STUDI ALTERNATIF PERENCANAAAN SISTEM RANGKA PEMIKUL MOMEN KHUSUS (SRPMK) DENGAN KOLOM BULAT PADA KANTOR PUSAT ESTIKES KEPANJEN MALANG
Kolom merupakam elemen vertikal suatu struktur yang berfungsi menahan
beban aksial dan momen sebagai akibat beban gravitasi dan beban lateral yang
bekerja pada struktur. Oleh karena itu, kolom memegan penampang penting pada
keutuhan struktur, apabila kolom mengalami kegagalan akan berakibat pada
keruntuhan struktur bangunan atas gedung. perbedaan kolom bulat dan kolom
persegi sangkat mendasar. Jika ditinjau dari tulangan sengkang, kolom bulat
perpenampang spiral memiliki jarak sengkang yang berdekatan diabnding dengan
kolom dengan kolom persegi yang mempunya bentuk sengkang tunggal dan jarak
antara yang relatif besaar.
Kolom bulat yang menghasilkan kapsitas penampang, gaya – gaya dalam
seperti gaya aksial; gaya geser; gaya momen, dan simpangan (maximum
displacement) sehingga dalam skripsi ini untuk mengetahui desain kolom bulat
yang efisien dan efikas didalam perencanaan.
Hasil yang diperoleh dari perenanaan struktur gedung dengan kolom bulat
pada gedung kantor pusat stikes kepanjen malang dengan program bantu STAAD
PRO V 8, yang ditinjau dari kapasitas penampang dengan luas mutu beton kolom
bulat menghasilkan ØPn (aksial nominal) = 3988,690 kN, ØMn ( Momen nominal
) = 478,812 kNm, Vn (Geser nominal) = 681629,848 N. Sehingga kolom bulat
memiliki kapasitas penampang yang lebih besar dan efektif. Ditinjau dari rasio
dan gaya-gaya dalam struktur, kolom bulat memiliki gaya aksial = 0,021,
kekakuan struktur pada kolom bulat memiliki simpangan (maximum
displacements) yang lebih besar dari kolom persegi. Sehingga kekakuan pada
kolom bulat lebih tinggi dengan kolom persegi
Recommended from our members
Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors.
Aim: Genomically matched trials in primary brain tumors (PBTs) require recent tumor sequencing. We evaluated whether circulating tumor DNA (ctDNA) could facilitate genomic interrogation in these patients. Methods: Data from 419 PBT patients tested clinically with a ctDNA NGS panel at a CLIA-certified laboratory were analyzed. Results: A total of 211 patients (50%) had ≥1 somatic alteration detected. Detection was highest in meningioma (59%) and gliobastoma (55%). Single nucleotide variants were detected in 61 genes, with amplifications detected in ERBB2, MET, EGFR and others. Conclusion: Contrary to previous studies with very low yields, we found half of PBT patients had detectable ctDNA with genomically targetable off-label or clinical trial options for almost 50%. For those PBT patients with detectable ctDNA, plasma cfDNA genomic analysis is a clinically viable option for identifying genomically driven therapy options
Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.
Recommended from our members
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
PurposeIn phase I testing, alisertib tablets with irinotecan and temozolomide showed significant antitumor activity in patients with neuroblastoma. This study sought to confirm activity of this regimen; evaluate an alisertib oral solution; and evaluate biomarkers of clinical outcomes.Patients and methodsWe conducted a two-stage phase II trial of alisertib tablets (60 mg/m2/dose × 7 days), irinotecan (50 mg/m2/dose i.v. × 5 days), and temozolomide (100 mg/m2/dose orally × 5 days) in patients with relapsed or refractory neuroblastoma. The primary endpoint was best objective response. A separate cohort was treated with alisertib at 45 mg/m2 using oral solution instead of tablets. Exploratory analyses sought to identify predictors of toxicity, response, and progression-free survival (PFS) using pooled data from phase I, phase II, and oral solution cohorts.ResultsTwenty and 12 eligible patients were treated in the phase II and oral solution cohorts, respectively. Hematologic toxicities were the most common adverse events. In phase II, partial responses were observed in 19 evaluable patients (21%). The estimated PFS at 1 year was 34%. In the oral solution cohort, 3 patients (25%) had first cycle dose-limiting toxicity (DLT). Alisertib oral solution at 45 mg/m2 had significantly higher median C max and exposure compared with tablets at 60 mg/m2. Higher alisertib trough concentration was associated with first cycle DLT, whereas MYCN amplification was associated with inferior PFS.ConclusionsThis combination shows antitumor activity, particularly in patients with MYCN nonamplified tumors. Data on an alisertib oral solution expand the population able to be treated with this agent